Organoid-Guided drug trial offers hope for cystic fibrosis patients with rare mutations

NCT ID NCT06468527

First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tested a combination of three drugs (Dirocaftor, Posenacaftor, Nesolicaftor) in 41 adults with cystic fibrosis who have rare gene mutations not covered by existing treatments. Participants were selected based on lab tests using their own intestinal organoids to predict if they would respond. The goal was to see if the drugs improve lung function and other measures over 8 weeks, with the aim of expanding treatment options for this underserved group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Integrata

    Verona, Italy

  • CHU de Nice

    Nice, France

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital de Santa Maria

    Lisbon, Portugal

  • Hôpital Larrey CHU Toulouse

    Toulouse, France

  • Instituto Giannina Gaslini

    Genova, Italy

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Ospedale Pediatrico Bambino Gesù

    Rome, Italy

  • Royal Brompton Hospital

    London, United Kingdom

  • Sahlgrenska University Hospital, Gothenburg CF center

    Gothenburg, Sweden

  • UMC Utrecht

    Utrecht, Utrecht, 3584 CX, Netherlands

  • UZ Leuven

    Leuven, Vlaams-Brabant, Belgium

  • University Hospital Southampton

    Southampton, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

Conditions

Explore the condition pages connected to this study.